CHIR Chiron (MM)

Chiron Corporation (NASDAQ: CHIR) today announced that it is recalling and withdrawing its measles, mumps and rubella (MMR) vaccine, MORUPAR(R). Chiron supplied approximately 5 million doses of MORUPAR vaccine in 2005, providing most of its production to a limited number of developing countries, largely via the United Nations Children's Fund (UNICEF) and the Pan American Health Organization (PAHO), and approximately 450,000 doses to Italy. The results of routine pharmacovigilance surveillance in Italy suggest that MORUPAR vaccine may be associated with a higher reported rate of adverse events following immunization than other MMR vaccine products. While recent and historical surveillance data indicate that adverse events remain rare, Chiron is recalling and withdrawing the vaccine as a precautionary measure. Pharmacovigilance results suggest that these adverse events occurred post-immunization and do not indicate any long-term risk for patients who have previously received the vaccine. The adverse events on which the recall and withdrawal are based are within a range of those commonly associated with vaccines, such as fever, allergic reactions and swelling of the glands. Chiron has been in communication with the relevant health authorities and informed them of its actions in order to enable them to find replacement supplies of MMR vaccine. Chiron will work closely with the World Health Organization (WHO) to assist it in conducting a thorough risk-benefit analysis of MORUPAR vaccine to determine whether it is appropriate for a limited quantity of the existing inventory to remain available for current public health programs such as those conducted by UNICEF and PAHO. In 2005, Chiron's sales of MORUPAR vaccine totaled approximately $10 million. As a result of this recall and withdrawal, as well as other adjustments identified by Chiron and recorded subsequent to the company's January 31, 2006, announcement of fourth-quarter and year-end 2005 financial results, Chiron has revised its 2005 earnings per share to $1.31 on an adjusted basis and $0.94 on a GAAP basis. Chiron has written off approximately $6.0 million of MORUPAR inventory in 2005 as a result of the withdrawal and has recorded approximately $1.7 million of product returns reserves in 2005 in connection with expected returns of 2005 product sales from the recall. The recall and withdrawal of MORUPAR, which Chiron produces in Italy, does not affect any of Chiron's other vaccines. Revised Year-End December 31, 2005, Financial Results For the year ended December 31, 2005, on an adjusted basis, Chiron reported revised income from continuing operations of $253 million, or $1.31 per share, a decrease of $0.03 per share from financial results as reported on January 31, 2006. On a GAAP basis, Chiron reported revised income from continuing operations of $180 million, or $0.94 per share, a decrease of $0.03 per share from financial results as reported on January 31, 2006. Revised Fourth-Quarter 2005 Financial Results For the fourth quarter of 2005, on an adjusted basis, Chiron reported revised income from continuing operations of $158 million, or $0.78 per share, a decrease of $0.03 per share from financial results as reported on January 31, 2006. On a GAAP basis, Chiron reported revised income from continuing operations of $138 million, or $0.68 per share, a decrease of $0.03 per share from financial results as reported on January 31, 2006. Chiron uses adjusted financial information to gain an understanding of the company's operating performance on a comparative basis. Adjusted amounts exclude special items relating to certain acquisitions and impairment losses on acquired intangible assets, which may not be indicative of the company's trends or potential future performance. Please refer to the tables at the end of this press release for more detail on these items and a reconciliation of the adjusted financial information to GAAP financial information; this information is also located at www.chiron.com in the Investors section under Financial Reports. All references to per-share amounts are per diluted share. About Chiron Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information, please visit www.chiron.com. Revised Financial Information 2005 financial information in PDF format http://www.chiron.com/investors/2389/chiron_financial.pdf 2005 financial information online http://www.chiron.com/investors/finreports/index.html This news release contains forward-looking statements, including statements regarding expected financial results for 2005 and the impact of the recall and withdrawal of MORUPAR MMR vaccine on Chiron's business, which involve risks and uncertainties and are subject to change. A discussion of the company's operations and financial condition, including factors that may affect its business and future prospects that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, is contained in documents the company has filed with the SEC, including the Form 10-K for the year ended December 31, 2004, and the Form 10-Q for the quarter ended September 30, 2005, and will be contained in all subsequent periodic filings made with the SEC. These documents identify important factors that could cause the company's actual performance to differ from current expectations, including, among others, litigation and investigations relating to influenza vaccines, the outcome of clinical trials, regulatory review and approvals, manufacturing capabilities, intellectual property protections and defenses, litigation, product liability claims, stock-price and interest-rate volatility, and marketing effectiveness. In particular, there can be no assurance that financial results for 2005 will be the same as preliminary results Chiron has announced today or that Chiron will be able to successfully develop and receive approval to market new products. In addition, the company may engage in business opportunities, the successful completion of which is subject to certain risks, including approval by Novartis AG, regulatory approvals and the integration of operations. Chiron does not undertake an obligation to update the forward-looking information the company is giving today. Financial results for 2005 included in this press release are preliminary. -0- *T CHIRON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended December 31, ----------------------------------------------------- 2005 2004 -------------------------- -------------------------- Adjusted Adjust- Actual Adjusted Adjust- Actual (1) ments (2) ments -------- ------- -------- -------- ------- --------- Revenues: Product sales, net $473,581 $- $473,581 $330,467 $- $330,467 Revenues from joint business arrangement 33,547 - 33,547 25,336 - 25,336 Collaborative agreement revenues 1,955 - 1,955 3,577 - 3,577 Royalty and license fee revenues 89,697 - 89,697 68,177 - 68,177 Other revenues 15,173 - 15,173 6,838 - 6,838 -------- ------- -------- -------- ------- --------- Total revenues 613,953 - 613,953 434,395 - 434,395 -------- ------- -------- -------- ------- --------- Operating expenses: Cost of sales 221,095 - 221,095 177,136 - 177,136 Research and development 109,271 - 109,271 129,392 - 129,392 Selling, general and administrative 125,391 - 125,391 137,727 - 137,727 Amortization expense - (11,969) 11,969 - (21,426) 21,426 Impairment loss on acquired intangible assets - (1,136) 1,136 - - - Other operating expenses 7,692 - 7,692 4,804 - 4,804 -------- ------- -------- -------- ------- --------- Total operating expenses 463,449 (13,105) 476,554 449,059 (21,426) 470,485 -------- ------- -------- -------- ------- --------- Income (loss) from operations 150,504 13,105 137,399 (14,664) 21,426 (36,090) Loss on disposal of assets (319) - (319) (2,092) - (2,092) Interest expense (7,683) - (7,683) (6,653) - (6,653) Interest and other income, net 19,644 - 19,644 14,390 - 14,390 Minority interest (498) - (498) (385) - (385) -------- ------- -------- -------- ------- --------- Income (loss) from continuing operations before income taxes 161,648 13,105 148,543 (9,404) 21,426 (30,830) Provision for (benefit of) income taxes 3,806 (6,685) 10,491 (2,351) 5,356 (7,707) -------- ------- -------- -------- ------- --------- Income (loss) from continuing operations 157,842 19,790 138,052 (7,053) 16,070 (23,123) ======== ======= ======== ======== ======= ========= Net income (loss)$157,842 $19,790 $138,052 $(7,053)$16,070 $(23,123) ======== ======= ======== ======== ======= ========= Basic earnings (loss) per share: Income (loss) from continuing operations $0.83 $0.72 $(0.04) $(0.12) ======== ======== ======== ========= Net income (loss) $0.83 $0.72 $(0.04) $(0.12) ======== ======== ======== ========= Diluted earnings (loss) per share: Income (loss) from continuing operations $0.78 $0.68 $(0.04) $(0.12) ======== ======== ======== ========= Net income (loss) $0.78 $0.68 $(0.04) $(0.12) ======== ======== ======== ========= Shares used in calculating basic earnings (loss) per share 190,679 190,679 186,813 186,813 ======== ======== ======== ========= Shares used in calculating diluted earnings (loss) per share 205,008 205,008 186,813 186,813 ======== ======== ======== ========= (1) Adjusted amounts exclude (a) the amortization expense on acquired intangible assets related to the acquisitions of PathoGenesis, Chiron Behring, Pulmopharm and PowderJect Pharmaceuticals and (b) an impairment loss of $1.1 million on acquired intangible assets from our acquisition of PowderJect Pharmaceuticals related to a contract manufacturing agreement. (2) Adjusted amounts exclude the amortization expense on acquired intangible assets related to the acquisitions of PathoGenesis, Chiron Behring, Pulmopharm and PowderJect Pharmaceuticals. CHIRON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Year Ended December 31, --------------------------------- 2005 --------------------------------- Adjusted Adjustments Actual (3) ---------- ---------- ----------- Revenues: Product sales, net $1,421,494 $- $1,421,494 Revenues from joint business arrangement 136,701 - 136,701 Collaborative agreement revenues 13,084 - 13,084 Royalty and license fee revenues 317,006 - 317,006 Other revenues 31,394 - 31,394 ---------- ---------- ----------- Total revenues 1,919,679 - 1,919,679 ---------- ---------- ----------- Operating expenses: Cost of sales 732,100 - 732,100 Research and development 433,891 - 433,891 Selling, general and administrative 501,193 - 501,193 Purchased in-process research and development - - - Amortization expense - (66,206) 66,206 Impairment loss on acquired intangible assets - (15,658) 15,658 Other operating expenses 20,515 - 20,515 ---------- ---------- ----------- Total operating expenses 1,687,699 (81,864) 1,769,563 ---------- ---------- ----------- Income from operations 231,980 81,864 150,116 Loss on disposal of assets (1,108) - (1,108) Interest expense (30,615) - (30,615) Interest and other income, net 86,692 - 86,692 Minority interest (2,221) - (2,221) ---------- ---------- ----------- Income from continuing operations before income taxes 284,728 81,864 202,864 Provision for income taxes 31,431 9,037 22,394 ---------- ---------- ----------- Income from continuing operations 253,297 72,827 180,470 ========== ========== =========== Gain from discontinued operations, net of taxes - - - ---------- ---------- ----------- Net income $253,297 $72,827 $180,470 ========== ========== =========== Basic earnings per share: Income from continuing operations $1.34 $0.96 ========== =========== Net income $1.34 $0.96 ========== =========== Diluted earnings per share: Income from continuing operations $1.31 $0.94 ========== =========== Net income $1.31 $0.94 ========== =========== Shares used in calculating basic earnings per share 188,448 188,448 ========== =========== Shares used in calculating diluted earnings per share 199,280 198,704 ========== =========== Year Ended December 31, ---------------------------------- 2004 --------------------------------- Adjusted Adjustments Actual (4) --------------------------------- Revenues: Product sales, net $1,268,303 $- $1,268,303 Revenues from joint business arrangement 118,246 - 118,246 Collaborative agreement revenues 18,044 - 18,044 Royalty and license fee revenues 289,561 - 289,561 Other revenues 29,201 - 29,201 ---------- ---------- ----------- Total revenues 1,723,355 - 1,723,355 ---------- ---------- ----------- Operating expenses: Cost of sales 675,944 - 675,944 Research and development 431,128 - 431,128 Selling, general and administrative 459,502 - 459,502 Purchased in-process research and development - (9,629) 9,629 Amortization expense - (84,503) 84,503 Impairment loss on acquired intangible assets - - - Other operating expenses 12,844 - 12,844 ---------- ---------- ----------- Total operating expenses 1,579,418 (94,132) 1,673,550 ---------- ---------- ----------- Income from operations 143,937 94,132 49,805 Loss on disposal of assets (3,247) - (3,247) Interest expense (26,093) - (26,093) Interest and other income, net 56,797 - 56,797 Minority interest (1,968) - (1,968) ---------- ---------- ----------- Income from continuing operations before income taxes 169,426 94,132 75,294 Provision for income taxes 42,357 21,126 21,231 ---------- ---------- ----------- Income from continuing operations 127,069 73,006 54,063 ========== ========== =========== Gain from discontinued operations, net of taxes 24,854 - 24,854 ---------- ---------- ----------- Net income $151,923 $73,006 $78,917 ========== ========== =========== Basic earnings per share: Income from continuing operations $0.68 $0.29 ========== =========== Net income $0.81 $0.42 ========== =========== Diluted earnings per share: Income from continuing operations $0.67 $0.28 ========== =========== Net income $0.80 $0.41 ========== =========== Shares used in calculating basic earnings per share 187,545 187,545 ========== =========== Shares used in calculating diluted earnings per share 190,202 190,202 ========== =========== (3) Adjusted amounts exclude (a) the amortization expense on acquired intangible assets related to the acquisitions of PathoGenesis, Chiron Behring, Pulmopharm and PowderJect Pharmaceuticals, (b) an impairment loss of $14.5 million on acquired intangible assets from our acquisition of PowderJect Pharmaceuticals related to a yellow fever vaccine and (c) an impairment loss of $1.1 million on acquired intangible assets from our acquisition of PowderJect Pharmaceuticals related to a contract manufacturing agreement. (4) Adjusted amounts exclude (a) the amortization expense on acquired intangible assets related to the acquisitions of PathoGenesis, Chiron Behring, Pulmopharm and PowderJect Pharmaceuticals and (b) Purchased in-process research and development related to the Sagres acquisition. CHIRON CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands) December December 31, 31, 2005 2004 ----------- ----------- Assets ------ Current assets: Cash, cash equivalents and short-term investments $686,074 $603,621 Accounts receivable, net of allowances 475,718 402,094 Inventories, net of reserves 231,666 221,154 Other current assets 198,394 167,154 ----------- ----------- Total current assets 1,591,852 1,394,023 Non-current investments in marketable debt securities 722,717 409,421 Property, plant, equipment and leasehold improvements, net 888,803 799,415 Other non-current assets 1,544,107 1,702,644 ----------- ----------- Total assets $4,747,479 $4,305,503 =========== =========== Liabilities and stockholders' equity ------------------------------------ Current liabilities $564,764 $434,444 Long-term debt 890,945 936,652 Long-term portion of capital lease 156,661 156,952 Non-current unearned revenue 27,359 26,175 Other non-current liabilities 112,828 140,226 Minority interest 10,779 9,350 Stockholders' equity 2,984,143 2,601,704 ----------- ----------- Total liabilities and stockholders' equity $4,747,479 $4,305,503 =========== =========== CHIRON CORPORATION SUPPLEMENTAL SCHEDULE OF COMPUTATION OF EARNINGS (LOSS) PER SHARE (Unaudited) (In thousands, except per share data) Three Months Ended December 31, 2005 2004 ------------------- ------------------ Adjusted Actual Adjusted Actual --------- --------- -------- --------- Computation for earnings (loss) per share - continuing operations Income (loss) (Numerator): Income (loss) from continuing operations $157,842 $138,052 $(7,053) $(23,123) Plus: Interest on 1.625% convertible debentures, net of taxes 1,586 1,586 - - Plus: Interest on Liquid Yield Option Notes, net of taxes 147 147 - - --------- --------- -------- --------- Income (loss) from continuing operations, plus impact from assumed conversions $159,575 $139,785 $(7,053) $(23,123) ====================================== Shares (Denominator): Weighted-average common shares outstanding 190,679 190,679 186,813 186,813 Additional shares from exercise of right under an agreement with Novartis (5) 3,448 3,448 - - Effect of dilutive securities: Stock options and equivalents 3,001 3,001 - - 1.625% convertible debentures 7,306 7,306 - - Liquid Yield Option Notes 574 574 - - --------- --------- -------- --------- Weighted-average common shares outstanding, plus impact from assumed conversions 205,008 205,008 186,813 186,813 ====================================== Basic earnings (loss) per share from continuing operations $0.83 $0.72 $(0.04) $(0.12) ========= ========= ======== ========= Diluted earnings (loss) per share from continuing operations $0.78 $0.68 $(0.04) $(0.12) ========= ========= ======== ========= Computation for earnings (loss) per share - net income (loss) Income (loss) (Numerator): Net income (loss) $157,842 $138,052 $(7,053) $(23,123) Plus: Interest on 1.625% convertible debentures, net of taxes 1,586 1,586 - - Plus: Interest on Liquid Yield Option Notes, net of taxes 147 147 - - --------- --------- -------- --------- Net income (loss), plus impact from assumed conversions $159,575 $139,785 $(7,053) $(23,123) ====================================== Shares (Denominator): Weighted-average common shares outstanding 190,679 190,679 186,813 186,813 Additional shares from exercise of right under an agreement with Novartis (5) 3,448 3,448 - - Effect of dilutive securities: Stock options and equivalents 3,001 3,001 - - 1.625% convertible debentures 7,306 7,306 - - Liquid Yield Option Notes 574 574 - - --------- --------- -------- --------- Weighted-average common shares outstanding, plus impact from assumed conversions 205,008 205,008 186,813 186,813 ====================================== Basic earnings (loss) per share from net income $0.83 $0.72 $(0.04) $(0.12) ========= ========= ======== ========= Diluted earnings (loss) per share from net income $0.78 $0.68 $(0.04) $(0.12) ========= ========= ======== ========= (5) On October 30, 2005 we exercised our right under an agreement with Novartis (as successor to Ciba-Geigy), dated as of November 20, 1994, as amended, to require Novartis or its affiliate to purchase shares of our common stock for an aggregate purchase price of $300.0 million at a per share purchase price of $43.50. On December 8, 2005, we closed on a sale of $300.0 million in newly issued shares of our common stock at a price of $43.50 per share to a subsidiary of Novartis. For purposes of calculating diluted earnings per share, the issued shares of this transaction are considered outstanding from October 30, 2005. As a result, the calculation of diluted earnings per share for the fourth quarter of 2005 included an additional 3.4 million shares. CHIRON CORPORATION SUPPLEMENTAL SCHEDULE OF COMPUTATION OF EARNINGS PER SHARE (Unaudited) (In thousands, except per share data) Year Ended December 31, 2005 2004 ------------------- ------------------ Adjusted Actual Adjusted Actual --------- --------- --------- -------- Computation for earnings per share - continuing operations Income (Numerator): Income from continuing operations $253,297 $180,470 $127,069 $54,063 Plus: Interest on 1.625% convertible debentures, net of taxes 6,357 6,357 - - Plus: Interest on Liquid Yield Option Notes, net of taxes 586 - - - --------- --------- --------- -------- Income from continuing operations, plus impact from assumed conversions $260,240 $186,827 $127,069 $54,063 ====================================== Shares (Denominator): Weighted-average common shares outstanding 188,448 188,448 187,545 187,545 Additional shares from exercise of right under an agreement with Novartis (6) 1,061 1,061 - - Effect of dilutive securities: Stock options and equivalents 1,887 1,887 2,657 2,657 1.625% convertible debentures 7,308 7,308 - - Liquid Yield Option Notes 576 - - - --------- --------- --------- -------- Weighted-average common shares outstanding, plus impact from assumed conversions 199,280 198,704 190,202 190,202 ====================================== Basic earnings per share from continuing operations $1.34 $0.96 $0.68 $0.29 ========= ========= ========= ======== Diluted earnings per share from continuing operations $1.31 $0.94 $0.67 $0.28 ========= ========= ========= ======== Computation for earnings per share - net income Income (Numerator): Net income $253,297 $180,470 $151,923 $78,917 Plus: Interest on 1.625% convertible debentures, net of taxes 6,357 6,357 - - Plus: Interest on Liquid Yield Option Notes, net of taxes 586 - - - --------- --------- --------- -------- Net income, plus impact from assumed conversions $260,240 $186,827 $151,923 $78,917 ====================================== Shares (Denominator): Weighted-average common shares outstanding 188,448 188,448 187,545 187,545 Additional shares from exercise of right under an agreement with Novartis (6) 1,061 1,061 - - Effect of dilutive securities: Stock options and equivalents 1,887 1,887 2,657 2,657 1.625% convertible debentures 7,308 7,308 - - Liquid Yield Option Notes 576 - - - --------- --------- --------- -------- Weighted-average common shares outstanding, plus impact from assumed conversions 199,280 198,704 190,202 190,202 ====================================== Basic earnings per share from net income $1.34 $0.96 $0.81 $0.42 ========= ========= ========= ======== Diluted earnings per share from net income $1.31 $0.94 $0.80 $0.41 ========= ========= ========= ======== (6) On October 30, 2005, we exercised our right under an agreement with Novartis (as successor to Ciba-Geigy), dated as of November 20, 1994, as amended, to require Novartis or its affiliate to purchase shares of our common stock for an aggregate purchase price of $300.0 million at a per share purchase price of $43.50. On December 8, 2005, we closed on a sale of $300.0 million in newly issued shares of our common stock at a price of $43.50 per share to a subsidiary of Novartis. For purposes of calculating diluted earnings per share, the issued shares of this transaction are considered outstanding from October 30, 2005. As a result, the calculation of diluted earnings per share for the year included an additional 1.1 million shares. CHIRON CORPORATION SUPPLEMENTAL REVENUE SUMMARY (Unaudited) (In thousands, except percentages) Current Prior Change Quarter Quarter from Change Q4 2005 Q3 2005 Prior QTR % --------------------------------- Product Sales Blood Testing Ortho $9,825 $7,023 $2,802 40% NAT 72,195 70,677 1,518 2% --------------------------------- Total Blood Testing 82,020 77,700 4,320 6% Vaccines Influenza vaccines 161,955 60,321 101,634 168% Meningococcal vaccines 8,968 11,635 (2,667) (23)% Travel vaccines (TBE, Rabies, Arilvax and Dukoral) 23,722 35,012 (11,290) (32)% Pediatric/Other vaccines 48,888 45,800 3,088 7% --------------------------------- Total Vaccines 243,533 152,768 90,765 59% Biopharmaceuticals Proleukin 31,259 31,028 231 1% TOBI 65,199 57,890 7,309 13% Betaseron(a) 40,545 36,927 3,618 10% Other 11,025 10,862 163 2% --------------------------------- Total Biopharmaceuticals 148,028 136,707 11,321 8% TOTAL PRODUCT SALES, NET $473,581 $367,175 $106,406 29% ================================= Revenues from joint business arrangement $33,547 $36,093 $(2,546) (7)% Collaborative agreement revenues 1,955 3,149 (1,194) (38)% Royalty and license fee revenues 89,697 70,726 18,971 27% Other revenues 15,173 2,470 12,703 514% --------------------------------- TOTAL REVENUES $613,953 $479,613 $134,340 28% ================================= Gross Margins Blood Testing 38% 42% (4)% Vaccines 45% 45% 0% Biopharmaceuticals 76% 71% 5% --------------------------- TOTAL GROSS MARGINS 53% 54% (1)% =========================== ---------------------------------------------------------------------- (a) Excludes Betaferon Royalty $14,122 $13,413 $709 5% ---------------------------------------------------------------------- Prior Change Year from Change Q4 2004 Prior % Year ------------------------ Product Sales Blood Testing Ortho $7,904 $1,921 24% NAT 63,705 8,490 13% ------------------------ Total Blood Testing 71,609 10,411 15% Vaccines Influenza vaccines 44,015 117,940 268% Meningococcal vaccines 9,309 (341) (4)% Travel vaccines (TBE, Rabies, Arilvax and Dukoral) 21,159 2,563 12% Pediatric/Other vaccines 57,656 (8,768) (15)% ------------------------ Total Vaccines 132,139 111,394 84% Biopharmaceuticals Proleukin 30,713 546 2% TOBI 53,276 11,923 22% Betaseron(a) 33,639 6,906 21% Other 9,091 1,934 21% ------------------------ Total Biopharmaceuticals 126,719 21,309 17% TOTAL PRODUCT SALES, NET $330,467 $143,114 43% ======================== Revenues from joint business arrangement $25,336 $8,211 32% Collaborative agreement revenues 3,577 (1,622) (45)% Royalty and license fee revenues 68,177 21,520 32% Other revenues 6,838 8,335 122% ------------------------ TOTAL REVENUES $434,395 $179,558 41% ======================== Gross Margins Blood Testing 40% (2)% Vaccines 28% 17% Biopharmaceuticals 70% 6% ------------------ TOTAL GROSS MARGINS 46% 7% ================== ---------------------------------------------------------------------- (a) Excludes Betaferon Royalty $12,798 $1,324 10% ---------------------------------------------------------------------- CHIRON CORPORATION SUPPLEMENTAL YTD REVENUE SUMMARY (Unaudited) (In thousands, except percentages) Twelve Months Ended Change Change December 31, from % Prior 2005 2004 Year ---------------------------------------- Product Sales Blood Testing Ortho $31,298 $27,844 $3,454 12% NAT 273,407 249,809 23,598 9% ---------------------------------------- Total Blood Testing 304,705 277,653 27,052 10% Vaccines Influenza vaccines 225,355 153,413 71,942 47% Meningococcal vaccines 43,361 27,739 15,622 56% Travel vaccines (TBE, Rabies, Arilvax and Dukoral) 147,507 96,864 50,643 52% Pediatric/Other vaccines 164,308 200,948 (36,640) (18)% ---------------------------------------- Total Vaccines 580,531 478,964 101,567 21% Biopharmaceuticals Proleukin 123,549 129,377 (5,828) (5)% TOBI 232,624 212,876 19,748 9% Betaseron(a) 142,238 130,572 11,666 9% Other 37,847 38,861 (1,014) (3)% ---------------------------------------- Total Biopharmaceuticals 536,258 511,686 24,572 5% TOTAL PRODUCT SALES, NET $1,421,494 $1,268,303 $153,191 12% ======================================== Revenues from joint business arrangement $136,701 $118,246 $18,455 16% Collaborative agreement revenues 13,084 18,044 (4,960) (27)% Royalty and license fee revenues 317,006 289,561 27,445 9% Other revenues 31,394 29,201 2,193 8% ---------------------------------------- TOTAL REVENUES $1,919,679 $1,723,355 $196,324 11% ======================================== Gross Margins Blood Testing 41% 42% (1)% Vaccines 31% 23% 8% Biopharmaceuticals 72% 72% 0% --------------------------------- TOTAL GROSS MARGINS 48% 47% 1% ================================= ---------------------------------------------------------------------- (a) Excludes Betaferon Royalty $59,955 $51,564 $8,391 16% ---------------------------------------------------------------------- *T